NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis.

@article{Bevers2009NCCNCP,
  title={NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis.},
  author={T. Bevers and B. Anderson and E. Bonaccio and S. Buys and M. Daly and P. Dempsey and W. Farrar and I. Fleming and J. Garber and R. Harris and A. Heerdt and M. Helvie and John G. Huff and N. Khakpour and Seema A. Khan and H. Krontiras and G. Lyman and E. Rafferty and S. Shaw and M. Smith and T. Tsangaris and Cheryl Williams and T. Yankeelov},
  journal={Journal of the National Comprehensive Cancer Network : JNCCN},
  year={2009},
  volume={7 10},
  pages={
          1060-96
        }
}
Key MethodThese guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties of any kind whatsoever regarding their content, use, or application…Expand
Breast Cancer Treatment Guidelines
TLDR
This chapter provides an overview of commonly used clinical practice guidelines, focusing directly on breast cancer treatment, that are available and designed to improve the health outcomes of patients. Expand
Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal.
TLDR
A systematic review was performed in accordance with the PRISMA guidelines using a predefined search strategy and summarizes in detail, the differences between ESMO and NCCN guidelines regarding genetic risk evaluation and screening, surgery, chemotherapy, endocrine treatment, targeted biological agents, radiotherapy, pregnancy and fertility and follow up. Expand
CE: Breast Cancer Screening: A Review of Current Guidelines.
TLDR
The guidelines of the American Cancer Society, the U.S. Preventive Services Task Force, and the National Comprehensive Cancer Network are reviewed and guidance to nurses is provided as they support and educate patients. Expand
Modification and implementation of NCCN guidelines on breast cancer in the Middle East and North Africa region.
TLDR
The MENA-NCCN Breast Cancer Guidelines modification process was the first initiative in the development of common practice guidelines in the region, and may serve as a foundation for theDevelopment of evidence-based practice standards, and improve collaborative projects and initiatives. Expand
Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative.
The Breast Health Global Initiative (BHGI) brought together international breast cancer experts to discuss breast cancer in low resource countries (LRCs) and identify common concerns reviewed in thisExpand
Clinical assessment of breast cancer risk based on family history.
  • K. Ready, B. Arun
  • Medicine
  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2010
TLDR
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer Risk Reduction and insight into the application of the guidelines in clinical practice are provided. Expand
Surgical considerations in locally advanced breast cancer patients receiving neoadjuvant chemotherapy
TLDR
The evolving concepts of breast conservation, immediate breast reconstruction and optimal management of the axilla are addressed and will facilitate the optimal diagnostic evaluation and management of locally advanced breast cancer patients. Expand
Personalized Screening for Breast Cancer: Rationale, Present Practices, and Future Directions
TLDR
Three ongoing, large-scale, randomized controlled clinical trials (WISDOM in the US, MyPEBS in Europe, and TBST in Italy) were identified through a search of the MEDLINE and US National Library of Medicine databases and aim to examine whether personalized risk-adapted screening can safely replace the current population-based approach and lead to rates of advanced-stage BC at diagnosis comparable with those of current screening regimens. Expand
Breast Cancer Patients' Views on the Use of Genomic Testing to Guide Decisions about Their Postoperative Chemotherapy
TLDR
Devoting greater efforts to explaining genomic test results to patients could be highly relevant in terms of the trade-off between the risk of unnecessary chemotherapy-related side effects and the loss of survival time possibly resulting from less aggressive treatment. Expand
Clinical indications: what is the evidence?
  • C. Lehman
  • Medicine
  • European journal of radiology
  • 2012
TLDR
MRI has the advantage of identifying cancers at a significantly earlier stage than cancers detected by mammography alone, and has transitioned into standard clinical practice as a screening tool for women at high risk of breast cancer. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG).
TLDR
Evidence exists that reducing the dose and/or altering the schedule of CMF ('modified' CMF) have compromised its efficacy in metastatic breast cancer, and adherence to the 'classical' dose and schedule is recommended when CMF is used in adjuvant therapy. Expand
Beyond randomized controlled trials
TLDR
The evaluation of organized mammography screening in a clinical setting is described and the benefit obtained from service screening in two Swedish counties is demonstrated. Expand
Ten‐Year Results of FAC Adjuvant Chemotherapy Trial in Breast Cancer
TLDR
Long-term follow-up of this study confirms the earlier observation that the FAC regimen is effective in reducing the risk of recurrence and prolonging the survival of high-risk patients. Expand
Combination chemotherapy as an adjuvant treatment in operable breast cancer.
TLDR
Long-term chemotherapy produced an acceptable toxicity, thus allowing the administration of a high percentage of drug dosage, and the effect of this therapy on survival and possible long-term side effects remain unknown. Expand
Randomized trial of breast self-examination in Shanghai: final results.
TLDR
Intensive instruction in BSE did not reduce mortality from breast cancer and programs to encourage BSE in the absence of mammography would be unlikely to reduce mortalityFrom breast cancer. Expand
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.
TLDR
Weekly paclitaxel therapy was well tolerated and demonstrated reasonable activity in this relatively heavily pretreated population with advanced disease, and further study of weekly pac litaxel in combination therapy is warranted. Expand
Benign breast disease and the risk of breast cancer.
TLDR
Risk factors for breast cancer after the diagnosis of benign breast disease include the histologic classification of a benign breast lesion and a family history of breast cancer. Expand
Docetaxel administered on a weekly basis for metastatic breast cancer.
  • H. Burstein, J. Manola, +8 authors E. Winer
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
PURPOSE To evaluate the safety and efficacy of weekly docetaxel in women with metastatic breast cancer. PATIENTS AND METHODS Twenty-nine women were enrolled onto a study of weekly docetaxel givenExpand
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.
TLDR
Based on the overall results, the capecitabine dose of 1,000 mg/m(2) twice daily merits consideration as "standard" for older patients who do not have severely impaired renal function. Expand
Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial.
TLDR
It is concluded that weekly doses of Adriamycin as single agent therapy for advanced breast cancer is as effective as the VAC combination delivered every third week, with considerably less toxicity. Expand
...
1
2
3
4
5
...